Friday, January 17, 2014 1:22:35 PM
Moreover, the fact that Eltoprazine fits strategically with our MANF Parkinson’s program and has received substantial non-dilutive funding to generate the highly statistically significant data produced in the most recent PD LID trial suggests that we are now well positioned from an asset standpoint and we will be seeking clinical data and upcoming milestones to support valuation
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM